Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:activeDuring |
mafodotin
|
| gptkbp:administrativeDivision |
IV infusion
once every three weeks |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
antibody-drug conjugate
C6490H10000N1710O2000S40 |
| gptkbp:clinicalTrials |
Phase 2
NCT03076491 NCT03269136 NCT03308939 NCT03486067 NCT03672318 |
| gptkbp:contraindication |
anemia
headache nausea vomiting diarrhea pregnancy breastfeeding constipation infection dry eye syndrome hypersensitivity to the drug eye pain vision changes active infection severe corneal disease |
| gptkbp:developedBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:dosageForm |
lyophilized powder for solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Belantamab mafodotin
|
| gptkbp:lastProduced |
2020
|
| gptkbp:mandates |
relapsed or refractory multiple myeloma
|
| gptkbp:marketedAs |
gptkb:Blenrep
|
| gptkbp:notableFeature |
gptkb:Carfilzomib
gptkb:Isatuximab Bortezomib Daratumumab Elotuzumab Lenalidomide Pomalidomide Thalidomide |
| gptkbp:patentStatus |
patented
|
| gptkbp:researchAreas |
oncology
|
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
regular ophthalmic examinations
|
| gptkbp:sideEffect |
fatigue
thrombocytopenia infusion-related reactions neutropenia corneal toxicity |
| gptkbp:storage |
store at 2°C to 8°C
|
| gptkbp:targets |
malignant plasma cells
|
| gptkbp:triggerType |
targets_B-cell_maturation_antigen_(BCMA)
|
| gptkbp:usedFor |
treatment of multiple myeloma
|
| gptkbp:weight |
approximately 150 kDa
|